Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

[1] Miller KM(2015)Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry Diabetes Care 38 971-978

[2] Foster NC(2013)Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 36 3411-3417

[3] Beck RW(2017)Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes Diabetes Res Clin Pract 130 121-129

[4] Khunti K(2011)Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs J Med Econ 14 646-655

[5] Wolden ML(2017)The risks of nocturnal hypoglycaemia in insulin-treated diabetes Diabetes Res Clin Pract 133 30-39

[6] Thorsted BL(2015)A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine Diabetes Obes Metab 17 1107-1114

[7] Andersen M(2015)New insulin glargine 300 Units.mL(-1) provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units.mL(-1) Diabetes Care 38 637-643

[8] Davies MJ(2015)Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes Diabetes Obes Metab 17 254-260

[9] Khunti K(2016)The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus J Am Assoc Nurse Pract 28 503-509

[10] Alsifri S(2017)Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus Diabetes Metab Syndr Obes 10 273-284

[1] Miller KM(2015)Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry Diabetes Care 38 971-978

[2] Foster NC(2013)Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 36 3411-3417

[3] Beck RW(2017)Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes Diabetes Res Clin Pract 130 121-129

[4] Khunti K(2011)Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs J Med Econ 14 646-655

[5] Wolden ML(2017)The risks of nocturnal hypoglycaemia in insulin-treated diabetes Diabetes Res Clin Pract 133 30-39

[6] Thorsted BL(2015)A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine Diabetes Obes Metab 17 1107-1114

[7] Andersen M(2015)New insulin glargine 300 Units.mL(-1) provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units.mL(-1) Diabetes Care 38 637-643

[8] Davies MJ(2015)Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes Diabetes Obes Metab 17 254-260

[9] Khunti K(2016)The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus J Am Assoc Nurse Pract 28 503-509

[10] Alsifri S(2017)Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus Diabetes Metab Syndr Obes 10 273-284